Equities analysts predict that Acceleron Pharma Inc (NASDAQ:XLRN) will report $3.37 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Acceleron Pharma’s earnings. The highest sales estimate is $4.40 million and the lowest is $2.76 million. Acceleron Pharma also reported sales of $3.37 million during the same quarter last year. The business is scheduled to report its next quarterly earnings report on Wednesday, March 7th.

On average, analysts expect that Acceleron Pharma will report full year sales of $3.37 million for the current fiscal year, with estimates ranging from $12.54 million to $14.30 million. For the next fiscal year, analysts anticipate that the firm will post sales of $27.28 million per share, with estimates ranging from $13.20 million to $37.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Acceleron Pharma.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.02. The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The company’s revenue was up .0% on a year-over-year basis. During the same quarter last year, the business posted ($0.55) EPS.

XLRN has been the subject of several recent analyst reports. Credit Suisse Group set a $51.00 price target on Acceleron Pharma and gave the company a “buy” rating in a research note on Tuesday, November 14th. ValuEngine lowered Acceleron Pharma from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Barclays lifted their price target on Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, September 20th. Cann restated a “hold” rating on shares of Acceleron Pharma in a research note on Tuesday, September 5th. Finally, HC Wainwright began coverage on Acceleron Pharma in a research note on Thursday, October 12th. They issued a “buy” rating and a $57.00 price target for the company. Two analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $44.56.

Acceleron Pharma (NASDAQ XLRN) traded up $1.18 during midday trading on Thursday, hitting $38.24. The company’s stock had a trading volume of 280,200 shares, compared to its average volume of 383,598. Acceleron Pharma has a twelve month low of $23.07 and a twelve month high of $40.35.

In other Acceleron Pharma news, Director Jean George sold 105,122 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $35.73, for a total value of $3,756,009.06. Following the sale, the director now owns 1,250 shares of the company’s stock, valued at $44,662.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Corp /De/ Celgene bought 745,592 shares of the business’s stock in a transaction on Monday, September 25th. The stock was purchased at an average cost of $37.00 per share, for a total transaction of $27,586,904.00. Following the transaction, the insider now owns 6,118,479 shares of the company’s stock, valued at $226,383,723. The disclosure for this purchase can be found here. 3.90% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP increased its position in shares of Acceleron Pharma by 416.3% during the third quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 2,352 shares during the period. BNP Paribas Arbitrage SA increased its holdings in Acceleron Pharma by 969.9% in the second quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 3,288 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in Acceleron Pharma in the third quarter valued at $225,000. Trexquant Investment LP purchased a new position in Acceleron Pharma in the third quarter valued at $266,000. Finally, PNC Financial Services Group Inc. increased its holdings in Acceleron Pharma by 57.8% in the second quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock valued at $258,000 after buying an additional 3,100 shares during the last quarter. 85.70% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/zacks-analysts-anticipate-acceleron-pharma-inc-xlrn-will-post-quarterly-sales-of-3-37-million/1776291.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Get a free copy of the Zacks research report on Acceleron Pharma (XLRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.